ENDOCUFF VISION® designed to improve visualisation of the colon
LONDON, UK, Thursday 12 May, 07:00 BST. Norgine B.V. today announced that ENDOCUFF VISION® is now available in Belgium, Netherlands and France. ENDOCUFF VISION® is a Class 1 sterile medical device attached to the end of the colonoscope that opens up the field of view by retracting folds during withdrawal. It is proven to help increase the detection of pre-cancerous polyps as part of bowel cancer screening.
Colorectal cancer is the second most common cause of cancer-related mortality in the world [1], with nearly 1.4 million new cases diagnosed worldwide and 412,000 people in Europe. [2], [3] The detection and removal of pre-cancerous adenomas during colonoscopy substantially reduces both the development of and death from colorectal cancer.[4]
Peter Martin, Chief Operating Officer, Norgine, commented “We are pleased to announce the launch of ENDOCUFF VISION® in these additional markets. ENDOCUFF VISION® is a new device that is proven to improve visualisation of the colon, thus increasing the detection of cancerous and precancerous cells. By doing so it helps patients and healthcare systems by allowing the prevention and treatment of colon cancer at an earlier stage than might otherwise be possible.”
Over the years, Norgine has strengthened its colon cancer prevention and detection portfolio to ensure quality in colonoscopy and ultimately enhance health outcomes for patients.
In Europe, Australia and New Zealand, ENDOCUFF VISION® is available through Norgine’s infrastructure including: Australia, Austria, Belgium, Finland, France, Denmark, Germany, Italy, Ireland, Netherlands, New Zealand, Norway, Portugal, Spain, Sweden, Switzerland and the UK.
In the US and Canada, ENDOCUFF VISION® is available through Olympus Corporation of the Americas.
To see how ENDOCUFF VISION® works click here
Ends
Notes to Editors:
About Norgine
Norgine is a European specialist pharmaceutical company that has been established for over 100 years. In 2015, Norgine’s total revenue was EUR 320 million and the company employs over 1,000 people.
Norgine provides expertise and ‘know how’ in Europe to develop, manufacture and market products that offer real value to healthcare professionals, payers and patients. Norgine’s approach and infrastructure is integrated and focused upon ensuring that Norgine wins partnership opportunities for growth.
Norgine is headquartered in the Netherlands and its global operations are based in Amsterdam and in Harefield, UK. Norgine owns a R&D site in Hengoed, Wales and two manufacturing sites, one in Hengoed, Wales and one in Dreux, France.
For more information, please visit www.norgine.com
In 2012, Norgine established a complementary business Norgine Ventures, supporting innovative healthcare companies through the provision of debt-like financing in Europe and the US. For more information, please visit www.norgineventures.com.
NORGINE and the sail logo are trademarks of the Norgine group of companies.
Media Contacts:
Isabelle Jouin, T: +44 (0)1895 453643
Charlotte Andrews, T: +44 (0)1895 453607
Follow us @norgine
[1] Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J et al. Cancer incidence and mortality patterns in Europe: Estimates for 40 countries in 2012. Eur J Cancer 2013;49:1374-1403
[2] Colorectal Cancer Statistics, World Cancer Research Fund International, http://www.wcrf.org/int/cancer-facts-figures/data-specific-cancers/colorectal-cancer-statistics [Accessed 9 May 2015]
[3] Zavoral M et al. Colorectal cancer screening in Europe. World J Gastroenterol 2009;15(47):5907-5915
[4] LeClercq CMC, Bouwens MWE, Rondagh, EJA et al. Postcolonoscopy colorectal cancers are preventable: a population-based study. Gut 2014;63:957-963